EU/3/19/2143

Table of contents

About

On 26 February 2019, orphan designation (EU/3/19/2143) was granted by the European Commission to Pharma Mar S.A., Spain, for lurbinectedin for the treatment of small cell lung cancer.

Key facts

Active substance
Lurbinectedin
Disease / condition
Treatment of small cell lung cancer
Date of first decision
26/02/2019
Outcome
Positive
EU designation number
EU/3/19/2143

Sponsor's contact details

Pharma Mar S.A.
Avda. de los Reyes, 1 
Pol. Ind. La Mina 
28770 Colmenar Viejo 
Madrid 
Spain
Tel. + 34 9182 34553
E-mail: abirigaray@pharmamar.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating